ProtoKinetix Inc. has just received the results of studies conducted by ITTEC Stem, Inc. at the University of Finland. These outstanding results using AAGP™ in the cryopreservation process for stem cells demonstrate the vital importance of this molecule in the expanding stem cell industry. This is the first series of tests using AAGP™ on human embryonic stem cells.
Using standard cryogenic protocol for stem cell storage, the addition of 2mg/ml of AAGP™ resulted in an amazing recovery of 87%. Traditional recovery rates after cryopreservation with DMSO (Dimethyl Sulphoxide) are typically between 30% and 40%.
Stem cells grown, after cryopreservation with AAGP™, maintain their identity as stem cells, not differentiated. Differentiation occurs when a stem cell has started to change into another defined cell, such as kidney, liver, skin, or even nerve cells. It is critically important that stored embryonic stem cells do not differentiate during storage.
The use of and research on human embryonic stem cells is being debated by every society in the world over moral and ethical issues. The ability of this molecule to dramatically increase the survivability and viability of human embryonic stem cells should assist in solving some of these highly contentious debates. Embryonic stem cells are the most versatile of the stem cell group, with the ability to transform into any cell in the human body.